ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 584

Association of Platelet Endothelial Cell Adhesion Molecule-1 and â1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis

Seung Cheol Shim1, Donghyuk Sheen2, Mi Kyoung Lim1 and Hyo Park1, 1Medicine, Eulji University Hospital, Daejeon, South Korea, 2Rheumatology, Eulji University Hospital, Daejeon, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Ankylosing spondylitis (AS)

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthritis and Psoriatic Arthritis - Pathogenesis, Etiology

Session Type: Abstract Submissions (ACR)

Background/Purpose: Genetic factors provide over 90% of the susceptibility to ankylosing spondylitis (AS) and recent studies have focused on non-major histocompatibility complex genes. The etiology of uveitis in AS has been suggested to involve two adhesion molecules including intercellular adhesion molecule and leukocyte functional antigen.

Platelet-endothelial cell adhesion molecule 1 (PECAM1), a member of the immunoglobulin superfamily, may be an important regulator of antigen induced cell activation of lymphocytes. The b1 integrin (ITGB1) can associate with different membrane proteins and cause signal transduction by interactions in the extracellular and trans-membrane domain. Therefore, we examined the association of PECAM1 and ITGB1 gene polymorphisms with development of uveitis in patients with AS.

Methods: We conducted a case–control study where 223 AS patients who met the Modified New York criteria and 239 ethnically matched controls were genotyped for 9 single nucleotide polymorphisms (SNPs) in the PECAM-1 promoter and gene. Genomic DNA was isolated from peripheral blood leukocytes by a standard phenol–chloroform method and a GoldenGate assay (Illumina, http://www.illumina.com) was used for genotyping.

Results: Conditional logistic regression was used to evaluate the association between the PECAM1 or ITGB1 SNPs with susceptibility to AS, and no significant association was found on both genes. However, in the subgroup analyses between AS patients with uveitis and those without, seven SNPs in PECAM1 gene were associated with the presence of uveitis, including rs1050382 (dominant model (DM), p=0.022), rs2812 (recessive model (RM), p=0.013), rs4968721 (DM, p=0.016), rs6808 (DM, p=0.011), rs6809 (DM, p=0.013), rs9899806 (DM, p=0.013) and rs9913080 (DM, p=0.019) (Table 1). In addition, seven polymorphisms in ITGB1 gene including rs11009147 (DM, p=0.012; co-dominant model (CDM), p=0.034), rs17468 (DM, p=0.012; CDM, p= 0.019), rs2153875 (CDM, p= 0.030), rs2230396 (DM, p=0.012; CDM, p=0.034), rs2488330 (DM, p=0.004; CDM, p=0.017), rs3780871 (DM, p=0.031) and rs7079624 (RM, p=0.004; CDM, p=0.017) were associated with uveitis development (Table 2).

Conclusion: This is the first analysis of the PECAM1 and ITGB1 gene polymorphisms in AS, demonstrating a clear association with uveitis in AS. Given the functional role of PECAM-1 and ITGB1 variants in the immune system, larger studies are now warranted to elucidate the association of PECAM-1 and ITGB1 in the pathogenesis of uveitis in AS.


Disclosure:

S. C. Shim,
None;

D. Sheen,
None;

M. K. Lim,
None;

H. Park,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-platelet-endothelial-cell-adhesion-molecule-1-and-a1-integrin-gene-polymorphisms-with-uveitis-development-in-ankylosing-spondylitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology